Syros to Present at Upcoming Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the development of medicines to control the
expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at
upcoming investor conferences. Details are as follows:
Cowen and Company 38 th Annual Health Care Conference
Date: Monday, March 12
Time: 12:00 p.m. ET
Location: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA
Oppenheimer 28 th Annual Healthcare Conference
Date: Wednesday, March 21
Presentation Time: 2:10 p.m. ET
Location: The Westin New York Grand Central, 212 East 42nd Street, New York, NY
A live webcast of each presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following each
presentation.
About Syros Pharmaceuticals
Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control
expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this
unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient
populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential
to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and
monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a
selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and
myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge,
Mass.
Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005660/en/